S

Supernus Pharmaceuticals
D

SUPN

36.270
USD
0.45
(1.26%)
Market Open
Volume
438
EPS
1
Div Yield
-
P/E
34
Market Cap
2,009,429,344
OverviewSignalsIdeasNews
Related Instruments
    A
    ACAD
    -0.240
    (-1.41%)
    16.790 USD
    ALNY
    ALNY
    -22.650
    (-8.77%)
    235.480 USD
    A
    AVDL
    -0.670
    (-5.79%)
    10.910 USD
    B
    BPMC
    -6.990
    (-7.31%)
    88.690 USD
    I
    ILMN
    -7.180
    (-5.05%)
    135.110 USD
    I
    IONS
    -2.970
    (-7.97%)
    34.290 USD
    N
    NBIX
    -5.465
    (-4.45%)
    117.410 USD
    S
    SGEN
    0
    (0%)
    0.000000 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    452.92 USD
    More
News

Title: Supernus Pharmaceuticals

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia inPD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.